companies / allyxthera-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 23,000,00023.0M | ○ |
|---|---|---|
| founded | 2019 | |
| hq | NEW HAVEN, Connecticut | |
| industry | unknown | |
| stage | null |
Allyx Therapeutics develops ALX-001, a candidate designed to preserve synapses in Alzheimer's and Parkinson's disease. It targets patients suffering progressive neurodegenerative disease. Differentiator: synaptic protection rather than the typical amyloid- or tau-targeting disease modification.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-01-01 | grant | 3,347,7033.3M | null | ○ |
Nginx, The SEO Framework, reCAPTCHA, Google Analytics, Google Tag Manager, FitVids.JS 4.24.3, jQuery Migrate 3.4.1, Divi, DoubleClick Floodlight, WordPress, PHP, MySQL
| fact | status | src |
|---|---|---|
| Grant, $3.3M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |